Maternal streptococcal B vaccine costeffective in sub-Sahara

Maternal streptococcal B vaccine costeffective in sub-Sahara PharmacoEconomics & Outcomes News 792, p17 - 2 Dec 2017 Maternal streptococcal B vaccine cost effective in sub-Sahara Streptococcal B (GBS) vaccination in pregnant women appears to be cost effective for the prevention of neonatal sepsis and meningitis in low-income countries in sub-Saharan Africa, according to findings of a study published in Vaccine. A decision tree and Markov model populated with data from published literature was used to evaluate the cost effectiveness of maternal GBS immunisation for the prevention of early-onset and late-onset GBS cases and deaths in infants in Ghana, Guinea-Basseau, Nigeria and Uganda, compared with no GBS immunisation. Cost effectiveness was assessed based on two benchmarks: 0.5 GDP and GDP per capita per disability-adjusted life-year (DALY) averted. The ** assumed cost of the vaccine was $7 per dose, and the assumed vaccine efficacy rate against serotypes was 70%. It was assumed that vaccine coverage was equivalent to the proportion of pregnant women who underwent four or more antenatal visits (ANC4). Maternal GBS vaccination was estimated to prevent 30%–34% of GBS cases and deaths in Uganda and Nigeria (ANC4 48% and 51%, respectively), 42-43% of cases and deaths in Guinea-Bissau (ANC4 65%), and 55%–57% of cases and deaths in Ghana (ANC4 87%). The estimated cost of GSB vaccination was $320–$350 per DALY averted in Guinea-Bissau, Ghana and Nigeria, which was below 50% of GDP per capita in these countries. The estimated cost of per DALY averted was higher in Uganda ($573). Sensitivity analyses found that the primary drivers of cost effectiveness were the cost per dose, and the incidences of GBS cases and GBS deaths. "The vaccine would be most cost-effective in countries like Nigeria, Guinea Bissau, and Ghana, where the case fatality ratio is high, and less cost-effective in countries like Uganda, where it is relatively low, but its cost/DALY is within the range for newer vaccines already included in the routine childhood vaccination schedules of all these, and other, low-income countries," said the authors. * gross domestic product ** 2014 US dollars Russell LB, et al. Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa. Vaccine : 9 Nov 2017. Available from: URL: http:// doi.org/10.1016/j.vaccine.2017.07.108 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Maternal streptococcal B vaccine costeffective in sub-Sahara

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/maternal-streptococcal-b-vaccine-costeffective-in-sub-sahara-vDToPf5XRc
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4540-4
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p17 - 2 Dec 2017 Maternal streptococcal B vaccine cost effective in sub-Sahara Streptococcal B (GBS) vaccination in pregnant women appears to be cost effective for the prevention of neonatal sepsis and meningitis in low-income countries in sub-Saharan Africa, according to findings of a study published in Vaccine. A decision tree and Markov model populated with data from published literature was used to evaluate the cost effectiveness of maternal GBS immunisation for the prevention of early-onset and late-onset GBS cases and deaths in infants in Ghana, Guinea-Basseau, Nigeria and Uganda, compared with no GBS immunisation. Cost effectiveness was assessed based on two benchmarks: 0.5 GDP and GDP per capita per disability-adjusted life-year (DALY) averted. The ** assumed cost of the vaccine was $7 per dose, and the assumed vaccine efficacy rate against serotypes was 70%. It was assumed that vaccine coverage was equivalent to the proportion of pregnant women who underwent four or more antenatal visits (ANC4). Maternal GBS vaccination was estimated to prevent 30%–34% of GBS cases and deaths in Uganda and Nigeria (ANC4 48% and 51%, respectively), 42-43% of cases and deaths in Guinea-Bissau (ANC4 65%), and 55%–57% of cases and deaths in Ghana (ANC4 87%). The estimated cost of GSB vaccination was $320–$350 per DALY averted in Guinea-Bissau, Ghana and Nigeria, which was below 50% of GDP per capita in these countries. The estimated cost of per DALY averted was higher in Uganda ($573). Sensitivity analyses found that the primary drivers of cost effectiveness were the cost per dose, and the incidences of GBS cases and GBS deaths. "The vaccine would be most cost-effective in countries like Nigeria, Guinea Bissau, and Ghana, where the case fatality ratio is high, and less cost-effective in countries like Uganda, where it is relatively low, but its cost/DALY is within the range for newer vaccines already included in the routine childhood vaccination schedules of all these, and other, low-income countries," said the authors. * gross domestic product ** 2014 US dollars Russell LB, et al. Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa. Vaccine : 9 Nov 2017. Available from: URL: http:// doi.org/10.1016/j.vaccine.2017.07.108 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off